Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 2,638 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 2,638 shares of the stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $105.16, for a total transaction of $277,412.08. Following the transaction, the chief executive officer now owns 210,377 shares in the company, valued at $22,123,245.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, July 15th, Steven Leonard Chapman sold 5,496 shares of Natera stock. The shares were sold at an average price of $111.66, for a total transaction of $613,683.36.
• On Monday, July 1st, Steven Leonard Chapman sold 37,500 shares of Natera stock. The shares were sold at an average price of $108.10, for a total transaction of $4,053,750.00.
• On Monday, June 17th, Steven Leonard Chapman sold 6,105 shares of Natera stock. The stock was sold at an average price of $111.61, for a total transaction of $681,379.05.
• On Wednesday, May 15th, Steven Leonard Chapman sold 6,779 shares of Natera stock. The stock was sold at an average price of $107.08, for a total transaction of $725,895.32.
• On Monday, April 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $93.14, for a total transaction of $380,383.76.

Natera Stock Up 1.0 %

Natera stock traded up $1.01 on Tuesday, hitting $106.52. 895,366 shares of the stock traded hands, compared to its average volume of 1,329,804. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36. The firm has a market cap of $13.08 billion, a P/E ratio of -34.14 and a beta of 1.48. The business’s fifty day simple moving average is $109.29 and its 200 day simple moving average is $91.89. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $117.23.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.16. The firm had revenue of $367.70 million during the quarter, compared to analyst estimates of $316.31 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. Natera’s quarterly revenue was up 52.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.23) EPS. As a group, sell-side analysts forecast that Natera, Inc. will post -2.43 earnings per share for the current year.

Hedge Funds Weigh In On Natera

Several large investors have recently modified their holdings of NTRA. Quent Capital LLC increased its holdings in Natera by 3.2% in the 1st quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock worth $293,000 after buying an additional 99 shares in the last quarter. GAMMA Investing LLC increased its holdings in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares in the last quarter. Arcadia Investment Management Corp MI increased its holdings in Natera by 47.8% in the 1st quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after buying an additional 174 shares in the last quarter. Fifth Third Bancorp increased its holdings in Natera by 3.0% in the 4th quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock worth $389,000 after buying an additional 179 shares in the last quarter. Finally, Oliver Lagore Vanvalin Investment Group increased its holdings in Natera by 109.3% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after buying an additional 389 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NTRA. Piper Sandler raised their target price on shares of Natera from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Tuesday, May 14th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a report on Friday, May 17th. TD Cowen raised their target price on shares of Natera from $123.00 to $137.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Jefferies Financial Group began coverage on shares of Natera in a report on Monday, June 3rd. They issued a “buy” rating and a $142.00 target price on the stock. Finally, BTIG Research lifted their price target on shares of Natera from $100.00 to $125.00 and gave the company a “buy” rating in a report on Monday, May 13th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $101.19.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.